3-(2,2-Dimethylbutyl)-5-methyl-1,2,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2,2-Dimethylbutyl)-5-methyl-1,2,4-oxadiazole
• 英文别名: 3-(2,2-dimethylbutyl)-5-methyl-1,2,4-oxadiazole
• 化学式: C₉H₁₆N₂O
• 分子量: 168.24
• InChiKey: MLLZQMLEMXGFRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
  申请人：Pfizer Inc.

  公开号：US11312713B2

  公开（公告）日：2022-04-26

  The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了式(I)的新型咪唑并[4,5-c]喹啉衍生物及其药学上可接受的盐 I 其中 R1、R2 和 R3 如说明书中所定义。本发明还涉及包含式 I 化合物的药物组合物，以及这些化合物在治疗与 LRRK2 有关的疾病中的用途，例如神经退行性疾病，包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20210355117A1

  公开（公告）日：2021-11-18

  The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R 1 , R 2 and R 3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.